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The present study aimed to characterize mutant alleles in Mucopolysaccharidosis II and evaluate possible reduction of mRNA amount
consequent to nonsense-mediated or nonstop mRNA decay pathways. A combination of different approaches, including real-time RT-PCR, were
used to molecularly characterize seventeen patients. Fifteen alleles were identified and nine of them were new. The novel alleles consisted of three
missense mutations (p.S71R, p.P197R, p.C432R), two nonsense (p.Q66X, p.L359X), two frameshifts (p.V136fs75X, p.C432fs8X), one allele
carrying two in-cis mutations [p.D252N;p.S369X], and a large deletion (p.G394_X551). Analysing these results it emerged that most of the
alterations resulted in mutants leading to mRNAs with premature termination codons, and therefore, potentially sensitive to mRNA surveillance
pathway. By using real-time RT-PCR, the mRNAs resulting (i) from substitutions that changed one amino acid to a stop codon (L359X, and
S369X), or caused the shifted reading frame with premature introduction of a stop codon (C432fs8X), (ii) from large deletion (p.G394_X551) that
included the termination codon, seemed to be subject to degradation by nonsense-mediated (i) or nonstop decay (ii) mechanisms, as mRNA was
strongly underexpressed. On the contrary, two mutations (Q66X and V136fs75X) produced transcripts evading mRNA surveillance pathway
despite both of them fulfilled the known criteria. These results confirm the wide variability of the mRNA expression levels previously reported and
represent a further exception to the rules governing susceptibility to nonsense-mediated decay. A close examination of the molecular basis of the
disease is becoming increasingly important for optimising the choices of available or forthcoming therapies such as, enzyme replacement therapy
or enzyme enhancement therapy.
© 2006 Elsevier B.V. All rights reserved.Keywords: Hunter; Mucopolysaccharidosis; IDS; real-time RT-PCR; Genotype–phenotype correlation; mRNA decay1. Introduction
Mucopolysaccharidosis type II (MPS II, Hunter syndrome;
OMIM #309900) [1] is a rare X-linked recessive lysosomal⁎ Corresponding author. Tel.: +39 010 5636 792/609; fax: +39 010 383983.
E-mail address: mirellafilocamo@ospedale-gaslini.ge.it (M. Filocamo).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.01.003storage disorder caused by the deficiency of the enzyme
iduronate-2-sulfatase (IDS; EC 3.1.6.13) involved in the
heparan sulfate and dermatan sulfate degradation. Two clinical
entities, mild and severe, are conventionally recognised. The
major clinical manifestations of the severe form are dysostosis
multiplex, organomegaly, mental retardation and death before
15years. Normal intelligence, short stature, survival into
adulthood characterize the mild form [2].
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spectrum of clinical severity. In absence of a standardized
index to score the severity, however, the classification of
the clinical phenotypes is difficult and generally is based on
the age at onset, degree of mental retardation and death
age.
The human IDS gene spans approximately 24kb in Xq28
and contains nine exons (Genbank-EMBL no. AF011889.1)
[3]. Its 1653-bp open reading frame (Genbank-EMBL no.
NM_000202) encodes a polypeptide of 550 amino acids
(Genbank-EMBL no.NP_000193) [3]. About 20 kb distal to
the functional IDS gene, a homologous pseudogene IDS2
(IDSP1) facilitating genetic rearrangements, is located (Gen-
bank-EMBL no. AF011889.1) [3]. To date, more than 300
different mutations have been reported in the IDS gene as the
cause of a wide spectrum of clinical severity. The mutational
profile consists of point mutations leading to missense (44%),
nonsense (10%) or splice-site alterations (9%); the small
insertions/deletions account for the 26% of the total mutations,
the remaining 11% are gross deletions, insertions, duplications
or complex rearrangements [4]. Amongst the different
mutations, it emerges that more than half of the alterations
(56%) results in mutant alleles that might lead to premature
termination codons.
Our MPS II series consists at present of 55 patients. The
molecular characterization of part of the group was reported in
previous studies [5–10]. We now report nine additional novel
mutant alleles, including missense, nonsense, frameshift muta-
tions and a large deletion, encountered in MPS II patients with
diverse phenotypes and ethnic backgrounds. In order to evaluate
possible reduction of mRNA amount consequent to nonsense-
mediated or nonstop mRNA decay pathways, we used the real-
time RT-PCR for quantification of mRNAs with nonsense or
frameshift mutations or lacking in-frame termination codonsTable 1
IDS mutant alleles encountered in 17 MPS II patients
Patient Age at diagnosis Age at present Age at death M
H2 10y 23y p
H4 3y 15y 6m p
H14 n.a. n.a. p
H25 5y 10y p
H30 n.a. n.a. [p
H118 3y 10y p
H145 3y 9y p
H146 4y 9y [p
H147 8y 10y u
H148 4y 6y p
H150 7y 12y u
H151 1y 3y p
H152 8y 10y p
H153 3y 4y G
H155 5m 6m p
H156 15m 16m p
H157 1y 7y p
y=years; m=months; n.a.=data not available; ‡ phenotypic classification is not app
a New alleles are underlined.
b Classification based on degree of mental retardation and death age.
c Polymorphic variant.[11,12]. A close examination of the molecular basis of the
disease is becoming increasingly important for optimising the
choices of available and forthcoming therapies such as, enzyme
replacement therapy (ERT) or enzyme enhancement therapy
(EET) [13,14].
2. Materials and methods
2.1. Patients
Seventeen unrelated patients with diverse phenotypes and ethnic back-
grounds were examined (Table 1). The diagnosis was based on clinical data as
well as on demonstration of high excretion of dermatan sulfate and heparan
sulfate in urine, and IDS deficiency in peripheral white blood cells or fibroblasts
or lymphoblasts. Table 1 reports the patients' clinical phenotype that ranged
from mild (no mental retardation, short stature), intermediate (mild retardation
and moderate hyperkinetic behaviour) to severe (early mental retardation,
pronounced behavioural disturbance, death before 15 years).
2.2. Controls
The control group consisted of 50 DNA samples from non-correlated female
healthy subjects.
The samples were obtained from the “Cell Line and DNA Bank from
Patients affected by Genetic Diseases” collection, situated at G. Gaslini Institute
[15].
2.3. Ethical aspects
Following ethical guidelines, the patient and control samples were obtained
for analysis and storage with written informed consent. The consent has been
sought using a form approved by local Ethics Committee.
2.4. Enzymatic assay
Iduronate-2-sulfatase activity was determined in homogenates of leukocytes
and/or cell lines using the fluorescent substrate, 4-methylumbelliferyl-alpha-
iduronide-2-sulfate [16].utant alleles a Clinical phenotype b Ethnic background
.C432R Intermediate Italian
.Q66X Intermediate/severe Italian
.G394 _ X551 n.a. Spanish
.L359X Severe Italian
.C432fs8X;(p.T146Tc)] n.a. Portuguese
.P197R Intermediate/severe African
.E375_G394del Mild/intermediate Italian
.D252N;p.S369X] Mild Italian
nknown (p.T146Tc) Mild Ukrainian
.C422R Mild/intermediate Italian
nknown (p.T146Tc) Mild Italian
.V136fs75X Intermediate Italian
.E375_ G394del Mild/intermediate Albanian
ene-Pseudogene Rec Intermediate Romanian
.P358R ‡ Italian
.S71R ‡ Italian
.S333L Intermediate Italian
licable due to the patient's young age.
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Total DNA and RNAwere extracted from cultured fibroblasts (patients H2,
H4, H14, H25, H30, H118, H146, H150, H152) or lymphoblasts (patients H145,
H147, H151, H153, H155) or peripheral lymphocytes (patients H148, H156,
H157) using standard protocols or suitable kits (Qiagen).
IDS gene exons and exon–intron boundaries were amplified by using
specific primers designed on the genomic sequence (GenBank-EMBL accession
no. AF011889.1), as previously reported [5,7,17].
Putative mutations were confirmed by sequencing in both directions
duplicate PCR products as well as by digesting PCR products with the specific
restriction endonuclease whose recognition site was consequently altered. If
the mutations neither created nor destroyed a restriction site, the amplification
was carried out by PCR-mediated site direct mutagenesis that introduced a new
cleavage site of restriction [18]. The hypothesis of new possible genetic
polymorphisms was also excluded ascertaining that none of the 50 female
control individuals had these alterations.
Reverse transcription-polymerase chain reaction (RT-PCR) conditions were
previously reported [7].
The products from PCR and/or RT-PCR were purified and directly
sequenced using an ABI 377 DNA automated sequencer with dye terminator
cycle sequencing kits (Applied Biosystems).
Patients who resulted negative to conventional mutation screening of the
IDS gene underwent a PCR-based methodology, previously developed to
rapidly detect possible gene/pseudogene recombinations [10].
2.6. Real-time PCR on PE biosystems prism 7700
Primers and probe were designed (using the Primer Express 1.0 software
program, Applied Biosystems) to yield a product of 151bp, specific to exons
7 and 8. The probe contained 6FAM as the reporter fluorophore at its 5′-end
and TAMRA as the quencher at its 3′-end. FPLC-purified primers and HPLC-
purified probe were purchased from Roche Diagnostics. The following
primers (HF and HR) and probe (HPB) were used for the analysis: HF: 5′-
TGGACGATCTTCAGCTGGC-3′, HR: 5′-GCCGTCCTTCCAGGAACATA-
3′, HPB: 5′-FAM-ATCATGGGTGGGCTCTAGGTGAACATGG-TAMRA-3′.
GAPDH cDNA control was amplified using GAPDH Probe (JOE™ Probe),
GAPDH Forward Primer, and GAPDH Reverse Primer supplied by Applied
Biosystems (TaqMan® GAPDH Control Reagents-Human). ABI Prism 7700
sequence was used as detection system (Applied Biosystems). Reaction
volumes of 25μl were prepared in 96-well MicroAmp optical plates with
MicroAmp optical caps (Applied Biosystems). GAPDH and IDS amplifica-
tions were run in separate wells. The reagents included the TaqMan 23
Universal Master Mix [1X TaqMan buffer A, 5mM MgCl2 400μM dUTP,
200μM dATP, dCTP, dGTP (each), 8% glycerol, AmpliTaq Gold (0.025U/
μl), AmpErase UNG (0.01U/μl)], 200nM of each forward and reverse
primer, 100 nM of each probe and cDNA. Standard wells contained 500,
200, 100, 50, 20, 10pg of a normal male cDNA, test sample wells
contained 100pg of cDNA. No-template-control wells (without DNA) wereTable 2
IDS new mutations
Exon cDNAa mutation Restriction enzyme site Pro
2 c.196CNT PvuII (−) c p.Q
2 c.213CNG NlaIV (+) p.S
3 c.408_411del CTTT MaeIII (+) p.V
5 c.590CNG MaeIII (+) p.P
6; 8 [c.754GNA;c.1106CNG] MboI (−); Eco57I (−) c [p.
8 c.1075delC HphI (−) c p.L
9 c.1294TNC BbvI (+) p.C
9 c.1295_96dupTG – p.C
9 c.1191−?_1653+?del – p.G
a Genbank-EMBL: NM_000202. For cDNA numbering +1 corresponds to the A
b Genbank-EMBL: NP_000193; (+) and (−) symbols are for creation of a restrict
c New cleavage site of restriction introduced by PCR-mediated site direct mutageincluded as negative controls. Each test sample and standard were run in
triplicate. The same cDNA from a normal male served as standard in all the
procedures. GAPDH and IDS samples were always run simultaneously.
PCR conditions were 50 °C for 2 min, 95 °C for 10min, then 50 cycles of
95 °C for 15s and 60 °C for 1min. The runs were monitored via the
Sequence Detection Software 1.5. After each run, a semi-log amplification
plot was shown, in which the progression of the reactions along the PCR
cycles was indicated by the increase of the normalized reporter fluorescence
emission (ΔRn). A threshold in the linear region of the semi-log
amplification plot was established at an arbitrary value of the ΔRn
normalized reporter fluorescence emission. For each reaction, a CT value,
which is the number of cycles necessary to reach the threshold, was
identified. Following the standard curve method two standard curves were
generated, one for the GAPDH amplifications and one for the IDS
amplifications, using the CT values obtained from the standard wells and
their known cDNA amounts [19,20]. They were used to determine
expression of the IDS and GAPDH genes in each triplicate. IDS gene
expression was determined by the ratio between the mean value obtained
for IDS and GAPDH.
2.7. Mutation nomenclature
All mutations are described according to mutation nomenclature [21].3. Results and discussion
3.1. Mutation profile
Table 1 reports the mutational spectrum of IDS gene in the
seventeen unrelated patients of the present study. Fifteen alleles
were identified and nine of them were new (Table 2) and
consisted of three missense mutations (p.S71R, p.P197R, p.
C432R), two nonsense (p.Q66X, p.L359X), two frame shift
changes (p.V136fs75X and p.C432fs8X), one complex allele
carrying two in-cis mutations [p.D252N;p.S369X], and a large
deletion (p.G394_X551). Table 2 summarized the localization
of new alterations in relation to cDNA nucleotide numbering
and the resulting changes at protein level. The missense S71R
due to a CNG transversion at position c.213 differs from the
already described S71R that resulted from the CNA transition in
the same position [22]. The missense C432R mutation (Table 2)
is novel but another missense mutation affecting the same
codon (C432Y) was previously reported [23]. A third mutation
affecting the same codon [a duplication of the nucleotidetein b mutation Effect on coding
66X Premature chain termination at codon 66
71R Polar uncharged Ser→polar positively charged Arg
136fs75X Frameshift and chain termination at codon 211
197R Polar uncharged Pro→polar positively charged Arg
D252N;p.S369X] Polar negatively charged Asp→polar uncharged
Asn and chain termination at codon 369
359X Premature chain termination at codon 359
432R Polar uncharged Cys→polar positively charged Arg
432fs8X Frameshift and chain termination at codon 440
394_X551 ?
of the first ATG translation initiation codon.
ion site and loss of an existing one, respectively.
nesis [18].
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reading frame (C432fs8X)] was also identified in our series
(Tables 1 and 2). C432fs8X was associated with the
polymorphism T146T [24].T146T was the only alteration
identified in 2 mild MPSII patients of our series (Table 1).
3.2. Real-time RT-PCR of mRNAs with nonsense and frameshift
mutations and a deletion
Recently, it has been reported that mutations introducing
premature translation termination codons (PTCs) at a position
that is more than 50–55 nucleotides upstream of a splicing-
generated exon–exon junction trigger nonsense-mediated decay
(NMD). This mechanism is aimed at eliminating mRNAs
containing PTCs and thus helping limit the synthesis of
abnormal proteins [12]. Moreover, distinct mRNA surveillance
process, called nonstop decay, is responsible for depleting
mRNAs lacking in frame termination codons [11]. Hence, the
new substitutions we found to change one amino acid to a stop
codon (Q66X, L359X, and S369X), or cause the shifted reading
frame with premature introduction of a stop codon (V136fs75X
and C432fs8X), could result in unstable mRNAs, subject to
degradation by NMD [12]. Similarly, the nonstop decay
mechanism might also be hypothesised for the large deletion
that included exon 9 (G394_X551) with the start point at an
unknown position in the intron 8 and an end at an unknown
position downstream from polyA signal.
Possible mRNAs liable to be eliminated through NMD or
nonstop decay pathways, were evaluated by real-time RT-PCR
(Fig. 1). As expected, the transcripts that contained a nonsense
codon more than 50–55 nucleotides upstream of the splicing-
generated exon–exon junction (that are L359X, S369X) were
most likely subjected to NMD, as a reduction of 30% in mRNA
level was observed in comparison to the control samples. On theFig. 1. Real-time RT-PCR. Real-time RT-PCR quantification of mRNAs with nonsens
(G394_X551). The wild-type (wt) controls (4 different normal males) are represented
were used as counter-evidence. Note that the two missense R88P and R468Q werecontrary, real-time RT-PCR showed an impressive increase of
expression of the transcript with Q66X that we expected to
escape NMD because of a nonsense codon b50 nucleotides
upstream of the respective exon–exon junction. With regards to
the two mRNAs with frameshift, the results obtained by real-
time RT-PCR indicated that the mRNA with C432fs8X most
likely elicited the NMD mechanism, since its expression was
decreased, to 70% of the control samples. In contrast, the
mRNAwith V136fs75X evaded the RNA surveillance and, like
the transcript mentioned before (Q66X), showed a notable
increase of the expression. These results confirm the wide
variability of the mRNA expression levels previously reported
in several genetic diseases [25–32] and represent a further
exception to the rules governing susceptibility to NMD
pathway. Several genes are known to produce aberrant PTC-
transcripts that fulfil all the known criteria but still evade NMD
[25–31]. The proximity of non-sense codons to the native
initiation codon has been reported as possible determinant of
NMD evasion; this observation is supported by the knowledge
that mRNAs with short open reading frames may have a general
resistance to NMD [29,30]. NMD appears to be circumvented
also by reinitiation of translation downstream of the premature
termination codon [28,31]. It is clear, however, that the
existence of additional, identified [27] and unidentified [26]
determinants function to modulate the NMD sensitivity. More
recently, several studies indicate that the posttranscriptional
control of gene expression is much more complicated than
expected with mRNA metabolism being subject to diverse
regulatory mechanisms [33].
The other mechanism, nonstop decay, that functions to
remove cellular mRNAs lacking in-frame termination codons,
was hypothesised for the large deletion identified in the patient
#H14 and confirmed by real-time RT-PCR showing that mRNA
was strongly under expressed (to 9% of controls) (Fig. 1).e (Q66X, L359X, S369X), frameshift (C432fs, V136fs) mutations and a deletion
by stripped grey bars. mRNAs with missense mutations (R88P, R468Q, P197R)
identified in a previous study [7]. Error bars represent standard deviations.
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experiment and, as counter-evidence, 3 Hunter patients carrying
missense mutations (R88P, R468Q, P197R). As expected, the
expression of the mRNAs carrying missense mutations was in
the range of the controls (Fig. 1).
3.3. Genotype–phenotype correlations
Genotype–phenotype correlation, for MPS II disease, was
studied by means of expression of mutations in COS cells to
evaluate enzyme activity, processing and intracellular local-
ization [34] as well as by measurements of residual protein/
activity in plasma samples of affected patients [35,36]. In the
present study, the new 3 missense mutations (Table 2) seem
to be functionally important since two of the substituted
amino acids (S71 and P197) are evolutionarily conserved in
human and mouse iduronate sulfatase [37]; moreover, all the
amino acidic substitutions resulted in charge changes (S71R,
P197R and C432R). The supposed deleterious nature of these
mutations correlated with the phenotypes of the pt #H118
(P197R) and the pt #H2 (C432R), that ranged from
intermediate to severe (Table 1). The rare mutations C422R
and S333L were found associated with severe clinical
manifestations in previous reports [38–40]. However, we
detected these rare mutations in 2 patients (#H148 and
#H157) who showed phenotypes mild and intermediate at the
present age of 6 and 7 years old, respectively. Concerning the
frequent E375_G394del (commonly named G374G) that
activates a new cryptic splice site with consequent loss of
20 amino acids, previous studies demonstrated mostly
association with mild subtype likely to be imputable to the
presence of an additional normal transcript [40–45]. Others
reported the same mutation associated with intermediate and
severe phenotypes, although less frequently [23,46]. In our
series, this panethnic mutation (E375_G394del) always seems
to correlate with a phenotype ranging from mild to
intermediate. To clarify characterization of this mutation, we
analysed the available RNAs of our patients according to the
methodological approach reported by Bunge et al. [44]. No
additional normal transcript was found (data not shown), even
though a possible failure due to technical conditions cannot
be excluded. These findings support the hypothesis [41] that a
deleted in-frame transcript lacking non-homologous region
among human-derived sulfatase sequences [47] might produce
a residual protein/activity consistent with the phenotypes
observed by us.
With regard to the nonsense (Q66X, L359X) and frameshift
mutation (V136fs) resulting in the production of markedly
altered, generally truncated, IDS protein, the clinical pheno-
types ranged from intermediate to severe (pts #H4, #H25, #151)
(Table 1). The patient (#H146) carrying the mutant [D252N;
S369X] in which the stop codon, S369X, coexisted with the
missense D252N, which occurs on a completely-methylated
CpG site of exon 6 [48], showed an unexpected mild phenotype.
Currently, the patient, a 9-year-old boy, has mild coarsening of
facial features, macrocephaly, moderate joint stiffness and
normal development skills and intelligence.3.4. Conclusion
In accordance with the results from a worldwide survey, in
our series, in its entirety, gross rearrangements, frame shift
changes and nonsense mutations, all leading to truncated IDS-
peptides, account for 54% of the disease alleles. The remaining
46% of the alleles was due to missense mutations or small in
frame deletions.
The findings of the study confirm the already known IDS
mutational heterogeneity. The molecular characterization of
index case is very valuable for identifying female carrier in at
risk families. Also, the availability of molecular test corrobo-
rates the prenatal diagnosis procedures.
Finally, a close examination of the molecular basis of the
disease, from transcription to protein function, is becoming
increasingly important for optimising the choices of available
and forthcoming therapies. Recently, enzyme replacement
therapy (ERT) has been approved for MPS II and will soon be
available for all patients. However, if the recombinant enzyme is
an effective mean to reverse the substrate accumulation in
peripheral organs, it is unable to cross the blood–brain barrier
[49]. Another limitation is the problem of achieving enzyme
uptake in connective tissue cells, particularly in bone and
cartilagine tissue, known to be massively involved in MPS II.
For patients carrying missense mutations outside the catalytic
site, a possible treatment might rely on the development of other
strategies such as enzyme enhancement therapy (EET) in which
pharmacological chaperones are used to rescue misfolded or
unstable proteins with the aim to increase protein function. The
enormous advantage of these molecules is that they might cross
the blood–brain barrier and diffuse through connective tissue
matrices to reach target sites of pathology [13,14].
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